SCHEMBL472322

SCHEMBL472322

CN(C)c1ccc(Cl)cc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
TP53 P04637 2/20 0.57
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.52
TSHR P16473 3/20 0.52
CASP1 P29466 1/20 0.52
KDM4E B2RXH2 2/20 0.50
HSD17B10 Q99714 1/20 0.50
MYC P01106 2/20 0.49
NR4A1 P22736 1/20 0.49
FSCN1 Q16658 1/20 0.49
GAA P10253 3/20 0.48
KMT2A Q03164 2/20 0.48
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11871348 0.85 ALDH1A1 (0.53) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL6643737 0.85 SMN1; SMN2 (0.57) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL12505382 0.83 GAA (0.54) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL11105220 0.81 ALDH1A1 (0.49) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL7689156 0.81 C5AR1 (0.49) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL11193228 0.80 TP53 (0.59) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL4362314 0.80 ABL1 (0.56) ALDH1A1SMN1; SMN2KDM4EFSCN1GAA
SCHEMBL8482809 0.79 ALDH1A1 (0.50) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL28167214 0.79 ALDH1A1 (0.46) ALDH1A1TP53CA1CA2SMN1; SMN2
SCHEMBL27540670 0.79 ALDH1A1 (0.46) ALDH1A1TP53CA1CA2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2492746-B1 Chemically amplified negative resist composition and patterning process SHINETSU CHEMICAL CO (JP) 2019-11-20 EP disclosed
CN-105607426-B Polymer, chemical amplification negative resist composition and pattern forming method SHIN ETSU CHEMICAL COMPANY (JP) 2019-11-01 CN disclosed
EP-2492747-B1 Chemically amplified negative resist composition and patterning process SHINETSU CHEMICAL CO (JP) 2018-11-07 EP disclosed
EP-2270596-B1 Positive resist compostion and pattern forming process SHINETSU CHEMICAL CO (JP) 2018-07-25 EP disclosed
CN-104330955-B For the chemical-amplification positive anti-corrosion agent composition and patterning method of EB or EUV lithographic printings 信越化学工业株式会社 2018-05-25 CN disclosed
US-RE46765-E1 Chemically amplified negative resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2018-03-27 US disclosed
CN-104199255-B Chemistry amplification negative resist composition and patterning method for EB or EUV lithographic printings 信越化学工业株式会社 2018-03-13 CN disclosed
US-RE46736-E1 Chemically amplified negative resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2018-02-27 US disclosed
EP-2360527-B1 Patterning process using EB or EUV lithography SHINETSU CHEMICAL CO (JP) 2017-08-23 EP disclosed
EP-2360525-B1 Chemically amplified positive resist composition and pattern forming process SHINETSU CHEMICAL CO (JP) 2017-08-23 EP disclosed
EP-2146245-A2 Resist composition and patterning process Shinetsu Chemical Co., Ltd. (JP) 2010-01-20 EP disclosed
US-20100009299-A1 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2010-01-14 US disclosed
CN-101625524-A Photoresist composition and pattern forming method SHINETSU CHEMICAL CO 2010-01-13 CN disclosed
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed
EP-0603650-B1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AG (DE) 1997-04-02 EP disclosed
US-5516805-A 3,5-substituted aminobenzoylguanidines, their use as a medicament or diagnostic and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
EP-0603650-A1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-29 EP disclosed
EP-0023569-B1 DERIVATIVES OF CARBOXYLIC ACIDS, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM Dr. Karl Thomae GmbH (DE) 1983-06-22 EP disclosed
EP-0023569-A1 Derivatives of carboxylic acids, their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1981-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR ALDH1A1 2174/4885TP53 4513/4885CA1 3588/4885
US-20100009299-A1 Resist composition and patterning process ARF4, FGFR2, ARF5 ALDH1A1 2706/4885TP53 3130/4885CA1 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.